Monday, July 25, 2011

Sunday, July 24, 2011

Friday, July 22, 2011

New anti-cancer drugs plus chemo for breast cancer shows promise: Study

 New anti-cancer drugs plus chemo for breast cancer shows promise: Study...








ABT-737

                                                        


Docetaxel

Thursday, July 21, 2011

FDA approves AstraZeneca's anti-clotting drug Brilinta


 In continuation of my update on  Ticagrelor (Brilinta)......
FDA approves AstraZeneca's anti-clotting drug  Brilinta

Sunday, July 17, 2011

Tocotrienol could help reduce stroke damage

In continuation of my update on the benefits of  Vitamin  E


Tocotrienol could help reduce stroke damage

Saturday, July 16, 2011

Grape seed polyphenols may help prevent Alzheimer's disease

 In continuation of my update on the usefulness of polyphenols....
Grape polyphenols are also called Vineatrols (see structure : vineatrol / trans-resveratrol)



Tuesday, July 12, 2011

Sunday, July 10, 2011

FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis

We  know that, Rivaroxaban (structure below BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceuticals. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible....


Now FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery....

More....

Saturday, July 9, 2011

Thursday, July 7, 2011

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease



We know that Bardoxolone methyl (see the structurealso known as “RTA 402” and “CDDO-methyl ester) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation.......


Saturday, July 2, 2011

New and effective diabetes drug seeking approval

We know that, Dapagliflozin is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1 and 2 diabetes. Although dapagliflozin's method of action would operate on either type of diabetes or other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with Type 1 diabetes.Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucosereabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
New and effective diabetes drug seeking approval

Friday, July 1, 2011

New clot busting drug approved in UK

In continuation of my update on Ticagrelar.........

New clot busting drug approved in UK

Wednesday, June 29, 2011

Wednesday, June 22, 2011

Thursday, June 16, 2011

Liraglutide as Additional Treatment in Type 1 Diabetes

In continuation of my update on Liraglutide...
 Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide (below structure) , an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.


More....

Tuesday, June 14, 2011

New drug more effective than standard treatment to prevent heart-attack deaths

In continuation of my update on ticagrelor .....

Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor (see structure), was used instead of the standard treatment, clopidogrel...

More...

Wednesday, June 8, 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

We know that, PLX-4032(RG7204, Vemurafenib) is a highly selective inhibitor of BRAF kinase activity, with an IC50 of 44 nmol/L against V600E-mutant BRAF. BRAFV600E cancer-causing mutation occurs in most melanomas and about eight percent of all solid tumors....

More....


Tuesday, June 7, 2011

Formoterol drug improves fat burning and protein metabolism in men


We know that, Formoterol  or eformoterol  is a long-acting β2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD). It is marketed in four forms: a dry-powder inhaler (DPI), a metered-dose inhaler (MDI), an oral tablet, and an inhalation solution, under various trade names including Foradil/Foradile (Schering-Plough in the U.S., Novartis rest of world), Oxeze (AstraZeneca), Atock (Astellas), Atimos Modulite (Trinity-Chiesi), and Perforomist (Dey).

Now researchers lead by Dr. Paul Lee of  Garvan Institute of Medical Research in Sydney, have for the first time reports that research in animals has shown that formoterol can stimulate the growth of muscle and the burning of fat...

Formoterol drug improves fat burning and protein metabolism in men

Friday, June 3, 2011

Lyxumia®, as an add-on to basal Insulin, shows significant positive phase III results

Sanofi  announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide see structure above), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patientswith type 2 diabetes without significantly increasing their risk of hypoglycemia...

More...

Wednesday, June 1, 2011

Airtel: Switch off Diesel

Hi ,

I just signed a petition opposing Airtel's use of dirty diesel energy to power their cell phone towers.

Please read the mail below and take action.

Regards,



Dear friends,

Thanks to the telecommunications sector, every new call and SMS is hurting our environment. Lakhs of massive mobile network towers in our country run on dirty diesel.

Airtel is the market leader and trend-setter of the Indian telecom industry. If we get them to switch to renewable energy, it will set an example for the others to follow. Customers are the mainstay of this industry. Airtel would notice if customers ask them to make their calls green by using clean energy to power company’s mobile towers.

You should ask Airtel to switch to renewable energy.

http://www.greenpeace.org/india/en/What-We-Do/Stop-Climate-Change/Green-Electronics/switch-off-diesel/airtel-switch-off-diesel/

Several current and potential Airtel subscribers, asking them to switch to renewable energy will help put pressure on them to act. Since the company is bound to provide good service to its subscribers, they will not be able to ignore this feedback.

Like coal and nuclear, oil too is an unsustainable energy option. The Deepwater Horizon oil spill last year showed the dangers of our addiction to oil.[2] Studies conducted by the Intergovernmental Panel on Climate Change have shown that renewable energy is capable of powering the world.[3] Airtel needs to realise this and quit dirty energy.

Tell them now.

http://www.greenpeace.org/india/en/What-We-Do/Stop-Climate-Change/Green-Electronics/switch-off-diesel/airtel-switch-off-diesel/

Thanks a billion!

Photo of Abhishek Pratap

Abhishek Pratap
Climate and Energy Campaigner
Greenpeace India


Sources:

1. Dirty Talking? Case for telecom to shift from diesel to renewable, Greenpeace India, May 19, 2011
http://www.greenpeace.org/india/Global/india/docs/cool-it/reports/telecom-report-may-2011.pdf [PDF]

2. BP Oil Spill: How Bad Is Damage to Gulf One Year Later? Time magazine, April 19, 2011
http://news.yahoo.com/s/time/20110419/hl_time/08599206603100

3. Renewable energy can power the world, says landmark IPCC study, Guardian, May 9, 2011
http://www.guardian.co.uk/environment/2011/may/09/ipcc-renewable-energy-power-worlddr.umesh1969@gmail.com

You are receiving this email because someone you know sent it to you from the Greenpeace site. Greenpeace retains no information about individuals contacted through its site, and will not send you further messages without your consent -- although your friends could, of course, send you another message.

New drugs (Victrelis and Incivek ) encouraging for African Americans with hepatitis C

Current standard of treatment of interferon and ribavirun has only been effective in curing 38 to 40 percent of patients with chronic hepatitis C genotype 1. In clinical trials, Victrelis and Incivek, when working in concert with interferon and ribavirun, cured 65 to 75 percent of people with chronic disease and Victrelis-alone doubled the previous cure rate among African Americans......












Victrelis (Boceprevir)             







                                                                                                                                                                                                                                      Incivek (Telaprevir)


News Release Archives > New drugs encouraging for African Americans with hepatitis C

Tuesday, May 31, 2011

UCB,s new data for Cimzia® (certolizumab pegol) showed a rapid clinical response across a broad population of RA patients

UCB, announced data which showed that the addition of Cimzia® (certolizumab pegol) to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients. Company also claims that, consistent efficacy was observed across patients taking certolizumab pegol whether they had previously received TNF inhibitors or not and whether they received certolizumab pegol monotherapy or with concomitant DMARDs.....

Saturday, May 28, 2011

Incivek Approved for Hepatitis C

In continuation of my update on telaprevir...
Incivek Approved for Hepatitis C: "MONDAY, May 23 -- Incivek (telaprevir) has been approved by the U.S. Food and Drug Administration for adults with chronic hepatitis C infection who either haven't received standard interferon therapy or haven't responded to it.

Friday, May 27, 2011

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults


Levadex is designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (see above structure, DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines.
 MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults

Gout drug success for Novartis

Canakinumab (trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.

We know that, Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the US FDA on June 2009 and by the European Medicines Agency in October 2009. CAPS is a spectrum of autoinflammatory syndromes including familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease.

Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis but this trial has been discontinued. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease.


Gout drug success for Novartis

'Turkey tail' mushroom effectively suppresses prostate tumour development

We Know that, Turkey tail/Trametes versicolor — formerly known as Coriolus versicolor and Polyporus versicolor is an extremely common polypore mushroom which can be found throughout the world. Versicolor means 'of several colours' and it is true that this mushroom is found in a wide variety of different colours. T. versicolor is commonly called Turkey Tail because of its resemblance to the tail of the wild turkey. T. versicolor is recognized as a medicinal mushroom in Chinese medicine under the name yun zhi. In China and Japan T. versicolor is used as in immunoadjuvant therapy for cancer. Now Queensland University of Technology (QUT) researchers reported that, the mushroom  has the  medicinal benefits up to  100 per cent effective in suppressing prostate tumour development in mice during early trials......


'Turkey tail' mushroom effectively suppresses prostate tumour development

Tuesday, May 24, 2011

Thursday, May 19, 2011

Wednesday, May 18, 2011

New insect repellant may be thousands of times stronger than DEET

In continuation of mosquito repellants and DEET

Researchers report the identification and characterization of an Orco family agonist, VUAA1, using the Anopheles gambiae coreceptor (AgOrco) and other orthologues. These studies reveal that the Orco family can form functional ion channels in the absence of an odor-binding OR, and in addition, demonstrate a first-in-class agonist to further research in insect OR signaling. In light of the extraordinary conservation and widespread expression of the Orco family, VUAA1 represents a powerful new family of compounds that can be used to disrupt the destructive behaviors of nuisance insects, agricultural pests, and disease vectors alike...

New insect repellant may be thousands of times stronger than DEET

Ref : http://www.pnas.org/content/early/2011/05/04/1102425108#aff-1

Tuesday, May 17, 2011

Novel two-drug combination cures young patient with extensively drug-resistant tuberculosis


The combination of meropenem (above structure)  with clavulanate (right structure-potassium salt)  has high antimycobacterial activity in vitro against extensively drug-resistant Mycobacterium tuberculosis strains. Researchers report the successful use of this combination in association with linezolid (below structure)  in the management of an advanced extensively drug-resistant tuberculosis disease with complex second-line drug resistance in a 14-year-old teenager.







    2. http://www.einstein.yu.edu/uploadedFiles/PHD/2010%20Faculty%20Research%20Book.pdf

Monday, May 16, 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

First EffRx NDA accepted for filing by the FDA...

EffRx Pharmaceuticals SA, an Epalinges/Lausanne, Switzerland based drug delivery company announces that the New Drug Application (NDA) for the company's lead development program EX101 has been accepted for filing by the US Food and Drug Administration. EX101 is a proprietary buffered effervescent dosage form of alendronate sodium administered once weekly for treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. The EX101 formulation is the first and only effervescent bisphosphonate alternative to tablets. EX101 has a pleasant taste of strawberry and is quickly and completely dissolved. 

About Alendronate : Alendronic acid or alendronate sodium ( sold as Fosamax by Merck) is a bisphosphonate drug used for osteoporosis and several other bone diseases. It is marketed alone as well as in combination with vitamin D (2,800 U and 5600 U, under the name Fosamax+D). Merck's U.S. patent on alendronate expired in 2008 and Merck lost a series of appeals to block a generic version of the drug from being certified by the FDA. On February 6, 2008, the US FDA approved the first generic versions of alendronate, which were marketed by Barr Pharmaceuticals and Teva Pharmaceuticals USA. Teva Pharmaceuticals manufactures generic alendronate in 5-milligram, 10-milligram, and 40-milligram daily doses, and in 35-milligram and 70-milligram weekly doses, while Barr made generic alendronate in 70-milligram tablets, which were taken once weekly. Barr pharmaceuticals were subsequently acquired by Teva in July 2008...
Ref : http://www.effrx.com/firsteffrxnda.htm

Saturday, May 14, 2011